Boston Scientific ’s Shining Moment at TCT

Perhaps one of Boston Scientific’s greatest moments at the 31st Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, came when the company announced primary endpoint results from the EVOLVE Short DAPT clinical trial. The Marlborough, MA-based company said the trial evaluated its Synergy Bioabsorbable Polymer (BP) stent and that the EVOLVE is first prospective study initiated in the U.S. to examine the safety of a shortened duration of dual antiplatelet therapy (DAPT) in patients at high risk for bleeding. Results and demonstrated that a three-month regimen of DAPT is non-inferior to a 12-month or longer regimen in patients with an increased risk of bleeding after being treated with the Synergy. During TCT, Ian Meredith, Global CMO and Executive Vice President for Boston Scientific, spoke with MD+DI about the significance of the EVOLVE Short DAPT study. “I think the trial that defines [our presence at TCT] is the EVOLVE Short DAPT Study,” Meredith, told MD+DI. “The reason this is a landmark for us is … because the Synergy stent was designed for rapid healing and rapid endothelialization and at some point, in time, we could prove the concept that healing meant shorter durations of dual antiplatelet therapy. So, the question that remained, which was part of the original design principle almost 10 years ago, was could y...
Source: MDDI - Category: Medical Devices Authors: Tags: Cardiovascular Source Type: news